Technology

Boryung to Co-Market Celltrion Pharm Inc.’s Diabetes Drugs ‘Nesina’ and ‘Actos’… Secures 51.7 Billion Blockbuster Deal

Synergy Between Boryung’s ‘Sales Capabilities’ and Celltrion Pharm Inc.’s ‘Competitiveness of Original Products’ Joint Sales of Six Oral Diabetes Medications to Begin in January Next Year Boryung Pharma Solutions to Launch in 2027

Kim Seung-kwon
2026-11-16 16:58:03
[Edaily Reporter Kim Seung-kwon ] Boryung(003850)and Celltrion Pharm Inc. will jointly market the “Nesina” and “Actos” product lines for the treatment of type 2 diabetes. The strategy is to expand their presence in the domestic diabetes treatment market by combining Boryung’s sales and marketing capabilities with Celltrion Pharm Inc.’s competitive edge in original products.

Boryung announced on the 16th that it has signed a co-promotion agreement with Celltrion Pharm Inc. to jointly market the Nesina and Actos product lines.

Starting in January of next year, the two companies will jointly market the following products: △Nesina Tablets (alogliptin) △NesinaMet Tablets (alogliptin + metformin) △ Nesina Met Extended-Release Tablets (alogliptin + metformin) △ ActRo Tablets (pioglitazone) △ ActRo Met Tablets (pioglitazone + metformin) △ Nesina Act Tablets (alogliptin + pioglitazone)—six types of oral diabetes treatments—starting in January of next year.

At the “Nesina·Actos Joint Promotion and Exclusive Sales and Distribution Agreement Signing Ceremony” held on the 16th at Celltrion Pharm Inc.’s Gwacheon office, Jeong Woong-je, Head of Sales at Boryung Co., Ltd. (left), and Yoo Young-ho, CEO of Celltrion Pharm Inc. (right), pose for a commemorative photo. (Photo courtesy of Boryung)


Nesina is the original drug containing alogliptin, a DPP-4 (dipeptidyl peptidase-4) inhibitor, and received marketing approval from the U.S. Food and Drug Administration (FDA) in 2013. ActRo is the original product containing pioglitazone, a thiazolidinedione (TZD) that improves insulin resistance, and received FDA approval in 1999. Nesina Act is a fixed-dose combination containing both active ingredients in a single tablet and received FDA approval in 2013.

The Nesina and Actos product lines are medications that Celltrion acquired from the multinational pharmaceutical company Takeda in 2020. According to the pharmaceutical market research firm Ubiest, prescription sales last year totaled 51.7 billion won, placing them in the blockbuster category. A key strength is that the product lineup—ranging from single-ingredient to combination formulations—allows for prescriptions tailored to a patient’s condition and stage of treatment.

This agreement is expected to provide a boost to the diabetes business of “Boryung Pharma Solution,” Boryung’s specialized sales and marketing subsidiary set to launch next January. Boryung has been expanding its influence in the diabetes market by leading with products such as TruBuddy (dapagliflozin + pioglitazone) and TruDapa (dapagliflozin). By securing both DPP-4 inhibitors and original TZD-class drugs, the company is now able to offer a wide range of treatment options tailored to patient characteristics.

Yoo Young-ho, CEO of Celltrion Pharm Inc., stated, “We have entered into this partnership based on the experience both companies have accumulated in the domestic diabetes treatment market,” adding, “Together with Boryung, we will faithfully convey information about the Nesina and Actos product lines to the medical community to contribute to the effective treatment of type 2 diabetes patients and the improvement of their quality of life.”

Jeong Woong-je, Vice President of Boryung and the incoming CEO of Boryung Pharma Solution, emphasized, “By introducing Celltrion Pharm Inc.’s diabetes treatments Nesina and Actos—which have been validated in clinical practice—we have further strengthened Boryung’s diabetes treatment portfolio.” He added, “Leveraging Boryung Pharma Solution’s sales and marketing expertise, we will effectively communicate the value of these products to the medical community and create a new turning point for their growth.”

Economy

Corporation

IT·Science

Economy

LGELECTRONICS Increases R&D Investment by 27%… Capital Expenditures on HVAC Facilities Also Rise 2.7-Fold

LGELECTRONICS has invested approximately 3.6 trillion won in research and development (R&D) through the third quarter of this year. This represents an increase of more than 27% compared to the same pe…
2026-11-16 17:04:33

Corporation

'Balanced Growth in Fashion and Beauty' LF Reports 51.1 Billion Won in Q3 Operating Profit… Up 217%

LF achieved both revenue growth and improved profitability in the third quarter, driven by balanced growth across its in-house and imported fashion and beauty brands. LF(093050)According to the quarte…
2026-11-16 16:38:14

IT·Science

Boryung to Co-Market Celltrion Pharm Inc.’s Diabetes Drugs ‘Nesina’ and ‘Actos’… Secures 51.7 Billion Blockbuster Deal

Boryung(003850)and Celltrion Pharm Inc. will jointly market the “Nesina” and “Actos” product lines for the treatment of type 2 diabetes. The strategy is to expand their presence in the domestic diabet…
2026-11-16 16:58:03